National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Ixazomib (Ninlaro®)

Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

NCPE Assessment Process Ongoing
Rapid review received 23/11/2016
Rapid review completed 16/01/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 23/01/2017
Pre-submission consultation with Applicant 06/02/2017
Submission received from Applicant 01/06/2017
Preliminary review sent to Applicant 04/08/2017
NCPE assessment re-commenced 31/08/2017
Applicant factual accuracy check 20/11/2017
NCPE assessment re-commenced 04/12/2017
Applicant factual accuracy check 2 07/12/2017
NCPE assessment re-commenced 12/12/2017
NCPE assessment completed 18/12/2017
Full pharmacoeconomic assessment outcome Reimbursement not recommended


The HSE has approved reimbursement following confidential price negotiations – December 2018.